Sanofi ADR's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Sanofi ADR reported revenue of $43.6B (+6.2% year on year) and net income of $7.9B (+39.7% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net sales | $43.6B | $41.1B | $43.1B | — |
| Other revenues | $3.1B | $3.2B | $3.4B | — |
| Cost of sales | ($13.0B) | ($13.2B) | ($14.2B) | — |
| Gross profit | $33.7B | $31.1B | $32.2B | — |
| Research and development expenses | ($7.8B) | ($7.4B) | ($6.7B) | — |
| Selling and general expenses | ($9.5B) | ($9.2B) | ($10.7B) | — |
| Other operating income | $1.2B | $1.1B | $1.3B | — |
| Other operating expenses | ($5.7B) | ($4.4B) | ($3.5B) | — |
| Amortization of intangible assets | ($1.8B) | ($1.7B) | ($2.2B) | — |
| Impairment of intangible assets | ($2.2B) | ($248.0M) | ($896.0M) | — |
| Fair value remeasurement of contingent consideration | ($104.0M) | ($96.0M) | ($93.0M) | — |
| Restructuring costs and similar items | ($1.1B) | ($1.4B) | ($1.5B) | — |
| Other gains and losses, and litigation | ($255.0M) | ($470.0M) | ($38.0M) | — |
| Operating income | $6.3B | $7.3B | $7.9B | — |
| Financial expenses | ($563.0M) | ($1.1B) | ($1.3B) | — |
| Financial income | $394.0M | $519.0M | $591.0M | — |
| Income before tax and investments accounted for using the equity method | $6.2B | $6.7B | $7.2B | — |
| Income tax expense | ($1.0B) | ($1.2B) | ($1.6B) | — |
| Share of profit/(loss) from investments accounted for using the equity method | ($155.0M) | $60.0M | ($115.0M) | — |
| Net income from continuing operations | $5.0B | $5.6B | — | — |
| Net income excluding the exchanged/held-for-exchange Animal Health business | $2.9B | $64.0M | — | — |
| Net income | $7.9B | $5.6B | $5.4B | — |
| Net income attributable to non-controlling interests | $38.0M | $58.0M | $36.0M | — |
| Net income attributable to equity holders of Sanofi | $7.8B | $5.6B | $5.4B | — |
| Average number of shares outstanding (in shares) | 1.2B | 1.3B | 1.3B | — |
| Average number of shares after dilution (in shares) | 1.2B | 1.3B | 1.3B | — |
| Basic earnings per share excluding the exchanged/held-for-exchange Animal Health business (in euros per share) | $4.05 | $4.40 | — | — |
| Diluted earnings per share (in euros per share) | $4.03 | $4.39 | $4.30 | — |
| Basic earnings (loss) per share from discontinued operations | $2.35 | $0.04 | — | — |
| Basic earnings (loss) per share | $6.40 | $4.44 | — | — |
| Diluted earnings (loss) per share from discontinued operations | $2.34 | $0.04 | — | — |
| Diluted earnings (loss) per share | $6.37 | $4.43 | — | — |
| Line item | Jun 30, 2026 · YTD | Jun 30, 2025 · YTD | Jun 30, 2024 · YTD | Jun 30, 2023 · YTD |
|---|---|---|---|---|
| Net sales | $22.1B | $19.9B | $21.2B | $20.2B |
| Other revenues | $1.4B | $1.5B | $1.3B | $1.4B |
| Cost of sales | ($6.2B) | ($5.9B) | ($6.8B) | ($6.3B) |
| Gross profit | $17.4B | $15.5B | $15.6B | $15.2B |
| Research and development expenses | ($4.0B) | ($3.7B) | ($3.4B) | ($3.2B) |
| Selling and general expenses | ($4.8B) | ($4.5B) | ($5.3B) | ($5.2B) |
| Other operating income | $800.0M | $533.0M | $617.0M | $617.0M |
| Other operating expenses | ($3.4B) | ($2.5B) | ($2.0B) | ($1.4B) |
| Amortization of intangible assets | ($1.1B) | ($777.0M) | ($1.1B) | ($1.0B) |
| Impairment of intangible assets | ($1.0B) | ($210.0M) | $371.0M | ($15.0M) |
| Fair value remeasurement of contingent consideration | ($37.0M) | ($61.0M) | ($66.0M) | ($26.0M) |
| Restructuring costs and similar items | ($563.0M) | ($430.0M) | ($1.3B) | ($547.0M) |
| Other gains and losses, and litigation | ($95.0M) | ($57.0M) | ($442.0M) | ($73.0M) |
| Operating income | $3.2B | $3.8B | $3.0B | $4.3B |
| Financial expenses | ($465.0M) | ($361.0M) | ($586.0M) | ($370.0M) |
| Financial income | $137.0M | $184.0M | $281.0M | $286.0M |
| Income before tax and investments accounted for using the equity method | $2.8B | $3.6B | $2.7B | $4.2B |
| Income tax expense | ($871.0M) | ($711.0M) | ($463.0M) | ($730.0M) |
| Share of profit/(loss) from investments accounted for using the equity method | $2.0M | $85.0M | ($13.0M) | ($52.0M) |
| Net income from continuing operations | $2.0B | $3.0B | — | — |
| Net income from discontinued operations | $26.0M | $2.9B | — | — |
| Net income | $2.0B | $5.8B | $2.3B | $3.5B |
| Net income attributable to non-controlling interests | $40.0M | $25.0M | $17.0M | $26.0M |
| Net income attributable to equity holders of Sanofi | $2.0B | $5.8B | $2.2B | $3.4B |
| Basic earnings per share from continuing operations (in euros per share) | $1.61 | $2.40 | — | — |
| Basic earnings per share from discontinued operations (in euros per share) | $0.02 | $2.34 | — | — |
| Basic earnings per share (in euros per share) | $1.63 | $4.74 | $1.80 | $2.74 |
| Diluted earnings per share from continuing operations (in euros per share) | $1.60 | $2.39 | — | — |
| Diluted earnings per share from discontinued operations (in euros per share) | $0.02 | $2.33 | — | — |
| Diluted earnings per share (in euros per share) | $1.62 | $4.72 | $1.79 | $2.73 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Property, plant and equipment | $10.1B | $10.1B | $10.2B | $9.9B |
| Right-of-use assets | $1.5B | $1.5B | $1.7B | $1.8B |
| Goodwill | $41.3B | $43.4B | $49.4B | $49.9B |
| Other intangible assets | $26.3B | $22.6B | $24.3B | $21.6B |
| Investments accounted for using the equity method | $3.3B | $316.0M | $424.0M | $677.0M |
| Other non-current assets | $4.4B | $3.8B | $3.2B | $3.1B |
| Non-current income tax assets | $550.0M | $560.0M | $188.0M | $242.0M |
| Deferred tax assets | $8.6B | $8.0B | $6.4B | $5.4B |
| Non-current assets | $95.9B | $90.2B | $95.8B | $92.6B |
| Inventories | $10.2B | $9.4B | $9.7B | $9.0B |
| Accounts receivable | $8.4B | $7.7B | $8.4B | $8.4B |
| Other current assets | $4.1B | $3.8B | $3.5B | $3.5B |
| Current income tax assets | $397.0M | $724.0M | $391.0M | $374.0M |
| Cash and cash equivalents | $7.7B | $7.4B | $8.7B | $12.7B |
| Non-current assets or disposal groups classified as held for sale | $208.0M | $13.5B | $15.0M | $85.0M |
| Current assets | $31.0B | $42.6B | $30.7B | $34.0B |
| Total assets | $126.8B | $132.8B | $126.5B | $126.7B |
| Equity attributable to equity holders of Sanofi | $71.4B | $77.5B | $74.0B | $74.8B |
| Equity attributable to non-controlling interests | $334.0M | $350.0M | $313.0M | $368.0M |
| Total equity | $71.7B | $77.9B | $74.4B | $75.2B |
| Long-term debt | $14.2B | $11.8B | $14.3B | $14.9B |
| Non-current lease liabilities | $1.5B | $1.6B | $1.8B | $1.9B |
| Non-current liabilities related to business combinations and to non-controlling interests | $585.0M | $569.0M | $501.0M | $674.0M |
| Non-current provisions and other non-current liabilities | $6.7B | $8.1B | $7.6B | $6.3B |
| Non-current income tax liabilities | $2.1B | $1.5B | $1.8B | $2.0B |
| Deferred tax liabilities | $1.7B | $2.2B | $1.9B | $1.8B |
| Non-current liabilities | $26.8B | $25.8B | $27.9B | $27.6B |
| Accounts payable | $7.4B | $7.6B | $7.3B | $6.8B |
| Current liabilities related to business combinations and to non-controlling interests | $0 | $72.0M | $208.0M | $105.0M |
| Current provisions and other current liabilities | $15.6B | $14.2B | $13.7B | $12.0B |
| Current income tax liabilities | $751.0M | $697.0M | $597.0M | $574.0M |
| Current lease liabilities | $272.0M | $261.0M | $275.0M | $277.0M |
| Short-term debt and current portion of long-term debt | $4.3B | $4.2B | $2.0B | $4.2B |
| Liabilities included in disposal groups classified as held for sale | $54.0M | $2.1B | $13.0M | $10.0M |
| Current liabilities | $28.3B | $29.2B | $24.2B | $24.0B |
| Total equity and liabilities | $126.8B | $132.8B | $126.5B | $126.7B |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 |
|---|---|---|---|---|
| Property, plant and equipment owned | $10.4B | $9.6B | $10.3B | $9.8B |
| Right-of-use assets | $1.6B | $1.4B | $1.6B | $1.7B |
| Goodwill | $42.0B | $40.3B | $50.1B | $49.2B |
| Other intangible assets | $26.4B | $20.4B | $26.7B | $24.6B |
| Investments accounted for using the equity method | $3.2B | $3.6B | $315.0M | $538.0M |
| Other non-current assets | $4.7B | $4.1B | $3.3B | $3.0B |
| Non-current income tax assets | $569.0M | $541.0M | $129.0M | $240.0M |
| Deferred tax assets | $8.8B | $8.0B | $7.3B | $6.0B |
| Non-current assets | $97.5B | $87.9B | $99.7B | $95.1B |
| Inventories | $11.1B | $9.6B | $10.6B | $10.0B |
| Accounts receivable | $8.7B | $7.8B | $8.5B | $8.3B |
| Other current assets | $4.3B | $3.6B | $3.9B | $3.4B |
| Current income tax assets | $492.0M | $397.0M | $295.0M | $353.0M |
| Cash and cash equivalents | $6.3B | $15.4B | $6.8B | $8.0B |
| Assets held for sale | $557.0M | $238.0M | $2.0M | $267.0M |
| Current assets | $31.5B | $37.0B | $30.1B | $30.0B |
| Total assets | $129.1B | $125.0B | $129.8B | $125.4B |
| Equity attributable to equity holders of Sanofi | $69.2B | $70.0B | $72.7B | $72.6B |
| Equity attributable to non-controlling interests | $360.0M | $271.0M | $307.0M | $318.0M |
| Total equity | $69.6B | $70.3B | $73.0B | $72.9B |
| Long-term debt | $14.6B | $13.2B | $12.5B | $14.2B |
| Non-current lease liabilities | $1.7B | $1.5B | $1.7B | $1.8B |
| Non-current liabilities related to business combinations and to non-controlling interests | $652.0M | $564.0M | $527.0M | $563.0M |
| Non-current provisions and other non-current liabilities | $6.8B | $7.1B | $8.2B | $7.1B |
| Non-current income tax liabilities | $2.2B | $1.5B | $1.9B | $1.9B |
| Deferred tax liabilities | $1.6B | $1.7B | $1.8B | $1.9B |
| Non-current liabilities | $27.6B | $25.6B | $26.7B | $27.6B |
| Accounts payable | $7.2B | $7.1B | $7.4B | $7.4B |
| Current liabilities related to business combinations and to non-controlling interests | $0 | $0 | $201.0M | $154.0M |
| Current provisions and other current liabilities | $16.4B | $13.7B | $12.7B | $11.9B |
| Current income tax liabilities | $884.0M | $724.0M | $132.0M | $377.0M |
| Current lease liabilities | $227.0M | $252.0M | $279.0M | $253.0M |
| Short-term debt and current portion of long-term debt | $7.0B | $7.3B | $9.2B | $4.7B |
| Liabilities related to assets held for sale | $197.0M | $2.0M | $0 | $37.0M |
| Current liabilities | $31.9B | $29.1B | $30.0B | $24.8B |
| Total equity and liabilities | $129.1B | $125.0B | $129.8B | $125.4B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income attributable to equity holders of Sanofi | $7.8B | $5.6B | $5.4B | — |
| Net income excluding the exchanged/held-for-exchange Animal Health business | ($2.9B) | ($64.0M) | — | — |
| Net income attributable to non-controlling interests | $38.0M | $58.0M | $36.0M | — |
| Share of undistributed earnings from investments accounted for using the equity method | $290.0M | $82.0M | $295.0M | — |
| Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets | $5.7B | $3.6B | $4.8B | — |
| Gains and losses on disposals of non-current assets, net of tax | ($352.0M) | ($366.0M) | ($509.0M) | — |
| Net change in deferred taxes | ($2.4B) | ($802.0M) | ($970.0M) | — |
| Net change in non-current provisions and other non-current liabilities | ($100.0M) | $812.0M | ($136.0M) | — |
| Cost of employee benefits (stock options and share-based payments) | $313.0M | $278.0M | $283.0M | — |
| Impact of the workdown of acquired inventories remeasured at fair value | $126.0M | $10.0M | $20.0M | — |
| Other profit or loss items with no cash effect on cash flows generated by operating activities | $273.0M | $68.0M | $283.0M | — |
| Operating cash flow before changes in working capital | $8.8B | $9.2B | $9.5B | — |
| (Increase)/decrease in inventories | ($39.0M) | ($477.0M) | ($840.0M) | — |
| (Increase)/decrease in accounts receivable | ($1.2B) | ($28.0M) | ($397.0M) | — |
| Increase/(decrease) in accounts payable | $398.0M | $789.0M | $402.0M | — |
| Net change in other current assets and other current liabilities | $2.6B | ($899.0M) | $1.6B | — |
| Cash flows from (used in) operating activities, continuing operations | $10.6B | $8.6B | — | — |
| Net cash provided by/(used in) operating activities | $10.8B | $9.1B | $10.3B | — |
| Cash flows from (used in) operating activities, discontinued operations | $189.0M | $474.0M | — | — |
| Net cash provided by/(used in) operating activities of the discontinued Opella business | ($3.5B) | ($3.2B) | ($3.0B) | — |
| Acquisitions of consolidated undertakings and investments accounted for using the equity method | ($9.4B) | ($1.9B) | ($3.9B) | ($852.0M) |
| Acquisitions of other equity investments | ($684.0M) | ($623.0M) | ($134.0M) | — |
| Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax | $847.0M | $1.5B | $1.0B | — |
| Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax | $0 | $0 | $42.0M | — |
| Net change in other non-current assets | ($80.0M) | ($40.0M) | ($229.0M) | — |
| Cash flows from (used in) investing activities, continuing operations | ($12.8B) | ($4.3B) | — | — |
| Net cash provided by/(used in) continuing investing activities | ($2.4B) | ($4.4B) | ($6.2B) | — |
| Cash flows from (used in) investing activities, discontinued operations | ($36.0M) | ($109.0M) | — | — |
| Net cash inflow from the Opella transaction | $10.4B | — | — | — |
| Net cash provided by/(used in) investing activities of the discontinued Opella business (h) | 177.0M | 187.0M | 195.0M | — |
| to shareholders of Sanofi | ($4.8B) | ($4.7B) | ($4.5B) | — |
| to non-controlling interests, excluding BMS | ($38.0M) | ($38.0M) | ($61.0M) | — |
| Payments received/(made) on changes of ownership interest in a subsidiary without loss of control | $0 | $0 | ($3.0M) | — |
| Additional long-term debt contracted | $5.6B | $0 | $48.0M | — |
| Repayments of long-term debt | ($2.6B) | ($671.0M) | ($3.7B) | — |
| Repayments of lease liabilities | ($333.0M) | ($282.0M) | ($265.0M) | — |
| Net change in short-term debt and other financial instruments | ($1.1B) | $59.0M | $765.0M | — |
| Acquisitions of treasury shares and related tax effect | -5.0B | -302.0M | -593.0M | — |
| Cash flows from (used in) financing activities, continuing operations | ($8.2B) | ($5.8B) | — | — |
| Net cash provided by/(used in) continuing financing activities | ($8.2B) | ($5.8B) | ($8.1B) | — |
| Cash flows from (used in) financing activities, discontinued operations | ($48.0M) | ($12.0M) | — | — |
| Impact of exchange rates on cash and cash equivalents | ($47.0M) | ($13.0M) | ($32.0M) | — |
| Effect of Reclassification of Discontinued Operation | $167.0M | ($167.0M) | — | — |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | $216.0M | ($1.3B) | ($4.0B) | — |
| Cash and cash equivalents, beginning of period | $7.4B | $8.7B | $12.7B | — |
| Line item | Jun 30, 2026 · YTD | Jun 30, 2025 · YTD | Jun 30, 2024 · YTD | Jun 30, 2023 · YTD |
|---|---|---|---|---|
| Net income attributable to equity holders of Sanofi | $2.0B | $5.8B | $2.2B | $3.4B |
| Net (income)/loss from the discontinued Opella business | ($26.0M) | ($2.9B) | — | — |
| Non-controlling interests | $40.0M | $25.0M | $17.0M | $26.0M |
| Share of undistributed earnings from investments accounted for using the equity method | $94.0M | ($15.0M) | $110.0M | $196.0M |
| Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets | $2.9B | $1.8B | $1.4B | $1.8B |
| Gains and losses on disposals of non-current assets, net of tax | ($9.0M) | ($266.0M) | ($279.0M) | ($307.0M) |
| Net change in deferred taxes | ($218.0M) | ($539.0M) | ($780.0M) | ($446.0M) |
| Net change in non-current provisions and other non-current liabilities | $195.0M | ($212.0M) | $1.1B | ($716.0M) |
| Cost of employee benefits (stock options and other share-based payments) | $184.0M | $171.0M | $173.0M | $160.0M |
| Impact of the workdown of acquired inventories remeasured at fair value | $210.0M | $0 | $19.0M | $5.0M |
| Other profit or loss items with no cash effect on cash flows generated by operating activities | ($74.0M) | $106.0M | $26.0M | $196.0M |
| Operating cash flow before changes in working capital | $5.2B | $4.0B | $4.1B | $4.4B |
| (Increase)/decrease in inventories | ($958.0M) | ($635.0M) | ($886.0M) | ($1.2B) |
| (Increase)/decrease in accounts receivable | ($27.0M) | ($785.0M) | $14.0M | ($215.0M) |
| Increase/(decrease) in accounts payable | ($340.0M) | $187.0M | $82.0M | $497.0M |
| Net change in other current assets and other current liabilities | $735.0M | $620.0M | ($1.9B) | $73.0M |
| Net cash provided by/(used in) continuing operating activities | $4.6B | $3.4B | — | — |
| Net cash provided by/(used in) operating activities of the discontinued Opella business | $0 | $188.0M | — | — |
| Net cash provided by/(used in) operating activities | $4.6B | $3.6B | $1.4B | $3.6B |
| Acquisitions of property, plant and equipment and intangible assets | ($1.3B) | ($1.4B) | ($1.9B) | ($930.0M) |
| Acquisitions of consolidated undertakings and investments accounted for using the equity method | ($1.4B) | ($538.0M) | ($1.9B) | ($2.5B) |
| Acquisitions of other equity investments | ($189.0M) | ($423.0M) | ($208.0M) | ($56.0M) |
| Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax | $424.0M | $434.0M | $607.0M | $578.0M |
| Disposals of consolidated undertakings and investments accounted for using the equity method, net of tax | $78.0M | $0 | $0 | $15.0M |
| Net change in other non-current assets | ($32.0M) | ($32.0M) | ($41.0M) | ($215.0M) |
| Net cash provided by/(used in) continuing investing activities | ($2.4B) | ($2.0B) | — | — |
| Net cash provided by/(used in) investing activities of the discontinued Opella business | $0 | ($36.0M) | — | — |
| Net cash inflow/(outflow) from the Opella transaction | ($220.0M) | $10.7B | — | — |
| Net cash provided by/(used in) investing activities | ($2.6B) | $8.7B | ($3.4B) | ($3.1B) |
| Issuance of Sanofi shares | 18.0M | 29.0M | 21.0M | 31.0M |
| to equity holders of Sanofi | ($4.9B) | ($4.8B) | ($4.7B) | ($4.5B) |
| to non-controlling interests | ($25.0M) | ($27.0M) | ($31.0M) | ($49.0M) |
| Additional long-term debt contracted | $2.3B | $3.0B | $0 | $0 |
| Repayments of long-term debt | ($1.5B) | ($1.9B) | ($637.0M) | ($2.7B) |
| Repayment of lease liabilities | ($147.0M) | ($124.0M) | ($144.0M) | ($127.0M) |
| Net change in short-term debt and other financial instruments | $2.0B | $3.3B | $5.9B | $2.4B |
| Acquisitions of treasury shares and related tax effect | -1.0B | -4.0B | -302.0M | -363.0M |
| Net cash provided by/(used in) continuing financing activities | ($3.3B) | ($4.4B) | — | — |
| Net cash provided by/(used in) financing activities of the discontinued Opella business | $0 | ($48.0M) | — | — |
| Net cash provided by/(used in) financing activities | ($3.3B) | ($4.5B) | $89.0M | ($5.2B) |
| Impact of exchange rates on cash and cash equivalents | $19.0M | ($42.0M) | ($14.0M) | ($19.0M) |
| Cash and cash equivalents reclassified to Assets held for sale as of December 31, 2024 | $0 | $167.0M | — | — |
| Net change in cash and cash equivalents | ($1.3B) | $7.9B | ($1.9B) | ($4.7B) |
| Cash and cash equivalents at beginning of period | $7.7B | — | — | — |
| Cash and cash equivalents, end of period | $6.3B | $15.4B | $6.8B | $8.0B |
Sanofi ADR score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.